We aimed to comprehensively discuss the efficacy and safety of IDH inhibitors in IDH-mutated AML patients by combining the results of our meta-analysis with other current therapeutic agents for IDH-mutated AML patients. The gene discussed is IDH2; the disease is acute myeloid leukemia.